Key Takeaways & Executive Findings
- •• Vascular-lymphatic imbalance and immune microenvironment changes interact to accelerate intervertebral disc degeneration. • Increased VEGF expression in degenerated discs may aid nutrient supply but also elevates pro-inflammatory factors like MMP-3, inhibiting type II collagen synthesis. • The complex interplay between vascular-lymphatic disruption and immune microenvironment remains poorly understood, with current studies only revealing expression changes. • Further research is needed to elucidate the temporal and dynamic regulation of vascular-lymphatic and immune microenvironment changes in specific stages of disc degeneration.
Abstract
BACKGROUND: The pathological process of intervertebral disc degeneration is accompanied by angiogenesis-lymphatic imbalance and changes in the immune microenvironment, both of which play important roles in intervertebral disc degeneration. OBJECTIVE: To systematically summarize the roles of angiogenesis-lymphatic imbalance-related cytokines in intervertebral disc degeneration. METHODS: The first author searched relevant literature published between January 2000 and April 2025 in the PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) databases. The Chinese search terms included "intervertebral disc degeneration, vascular-lymphatic imbalance, angiogenesis, vascular endothelial growth factor (VEGF), lymphatic vessel, Prox-1, immune microenvironment." A total of 65 articles were ultimately included for review. RESULTS AND CONCLUSION: During intervertebral disc degeneration, the vascular-lymphatic system and immune microenvironment play crucial roles in maintaining disc homeostasis. When disc degeneration occurs, angiogenesis and lymphatic disruption increase inflammatory factors within the disc, leading to enhanced degradation of the extracellular matrix. Concurrently, changes in the immune microenvironment, characterized by increased immune cell infiltration, elevated levels of pro-inflammatory cytokines and chemokines, and activation of local immune responses, modulate vascular and lymphatic vessels, ultimately reducing disc repair capacity and inducing chronic pain, thereby exacerbating the degree of disc degeneration.
1. Introduction
Intervertebral disc degeneration is a major cause of chronic low back pain and neurological dysfunction, imposing a huge burden on social economy and public health. The intervertebral disc is composed of the nucleus pulposus, annulus fibrosus, and cartilaginous endplates, with unique blood supply characteristics. FOURNIE et al. [1] conducted a retrospective study on human intervertebral disc vascularization, pointing out that the cartilaginous endplates and annulus fibrosus have abundant blood supply early in life, but with aging, the blood supply gradually decreases, while the nucleus pulposus never develops blood vessels throughout life. The growth of blood vessels into the cartilaginous endplates and inner annulus fibrosus is usually associated with disc injury or tissue destruction, indicating that the degenerative process of the disc is often accompanied by abnormal angiogenesis.
Traditional views held that the adult intervertebral disc is avascular and alymphatic [2], with nutrition mainly provided by passive diffusion through the cartilaginous endplates. Recently, researchers have for the first time localized the expression of lymphatic vessel-specific markers, such as Prox-1 and LYVE-1, in the annulus fibrosus of healthy human intervertebral discs, revealing clear tubular lymphatic structures [3], overturning the previous understanding. During disc degeneration, neovascularization, increased vascular permeability, and reduced lymphatic vessel number lead to vascular-lymphatic imbalance and local immune microenvironment changes, exacerbating the degree of disc degeneration [3-6]. Simultaneously, immune microenvironment changes activate immune cells, affecting vascular-lymphatic imbalance and further aggravating disc degeneration. The interaction between vascular-lymphatic imbalance and immune microenvironment changes accelerates the progression of disc degeneration (Figure 1). This article summarizes the factors related to vascular-lymphatic imbalance, immune microenvironment changes and their effects, and the synergistic role of both in disc degeneration (Figure 2), aiming to provide new perspectives for research on the mechanisms of disc degeneration.
Loading authentic research manuscript (Pages 1–5)...
Du Yaxin, Zhao Xiaojuan, Wu Ruixia, Dong Yizhi, Song Xinyue, Fu Hongyang, She Yitong, Zhang Jialin, Zhu Yong (2026). Interaction between vascular-lymphatic system imbalance and immune microenvironment in intervertebral disc degeneration. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21407
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of vascular-lymphatic imbalance in intervertebral disc degeneration?
Vascular-lymphatic imbalance, characterized by abnormal angiogenesis and lymphatic disruption, contributes to disc degeneration by increasing inflammatory factors, degrading extracellular matrix, and impairing disc repair capacity.
How does the immune microenvironment interact with vascular-lymphatic changes in disc degeneration?
Immune microenvironment changes, including immune cell infiltration and pro-inflammatory cytokine elevation, modulate vascular and lymphatic vessels, while vascular-lymphatic imbalance alters the immune microenvironment, creating a vicious cycle that accelerates disc degeneration.
What are the key molecular players in vascular-lymphatic imbalance during disc degeneration?
Key molecules include vascular endothelial growth factor (VEGF), which promotes angiogenesis, and lymphatic markers such as Prox-1 and LYVE-1, which are involved in lymphatic vessel maintenance. In degeneration, VEGF is upregulated while lymphatic markers may be reduced.
Why is the interaction between vascular-lymphatic and immune systems important for disc degeneration therapy?
Understanding this interaction can reveal novel therapeutic targets to restore disc homeostasis, potentially by modulating angiogenesis, lymphangiogenesis, or immune responses to halt or reverse degeneration.
What are the current research gaps in this field?
Current studies mainly describe expression changes of related factors but lack systematic elucidation of regulatory relationships. The temporal and dynamic regulation of vascular-lymphatic and immune microenvironment changes in specific stages of disc degeneration requires further investigation.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.